



CCM DUOPHARMA BIOTECH BERHAD (524271-W)
 (Incorporated in Malaysia)
UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
FOR THE PERIOD ENDED 30 JUNE 2011

	INDIVIDUAL PERIOD		CUMULATIVE PERIOD	
	CURRENT YEAR QUARTER 6/30/2011 RM'000	PRECEDING YEAR CORRESPONDING QUARTER 6/30/2010 RM'000	CURRENT YEAR TO DATE 6/30/2011 RM'000	PRECEDING YEAR CORRESPONDING PERIOD 6/30/2010 RM'000
Revenue	35,345	35,982	68,329	64,777
Cost of Sales	(19,871)	(20,710)	(39,228)	(37,636)
Gross Profit	15,474	15,272	29,101	27,141
Other operating income	210	216	407	402
Distribution costs	(2,557)	(2,757)	(5,125)	(5,488)
Administration expenses	(3,242)	(2,341)	(6,085)	(4,334)
Other operating expenses	(582)	(590)	(1,111)	(1,117)
Profit from operations	9,303	9,800	17,187	16,604
Finance costs	(11)	(10)	(21)	(22)
Profit before taxation	9,292	9,790	17,166	16,582
Taxation	(2,360)	(2,484)	(4,310)	(4,146)
Profit after tax for the period	6,932	7,306	12,856	12,436
Other comprehensive income	-	-	-	-
Total other comprehensive income for the period	6,932	7,306	12,856	12,436
Profit attributable to:				
Shareholders of the Company	6,932	7,306	12,856	12,436
Minority interest	-	-	-	-
	6,932	7,306	12,856	12,436
Total other comprehensive income attributable to:				
Shareholders of the Company	6,932	7,306	12,856	12,436
Minority interest	-	-	-	-
	6,932	7,306	12,856	12,436
Earnings per share (sen)				
Basic (based on weighted average)	4.99	5.26	9.26	8.96
Diluted (based on weighted average)	4.99	5.26	9.26	8.96

(The Condensed Consolidated Income Statement should be read in conjunction with the Audited Financial Statements for the year ended 31 December 2010 and the accompanying explanatory notes attached to the interim financial statements.)



CCM DUOPHARMA BIOTECH BERHAD (524271-W)
 (Incorporated in Malaysia)
UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION
AS AT 30 JUNE 2011

	AS AT END OF CURRENT PERIOD 30/6/2011 RM'000	AS AT PRECEDING FINANCIAL YEAR ENDED 31/12/2010 RM'000
ASSETS		
Property, Plant and Equipment	100,196	100,249
Total non-current assets	100,196	100,249
Inventories	39,472	34,003
Trade & Other Receivables	37,220	34,804
Related Company	1,366	951
Current tax assets	362	-
Assets classified as held for sale	1,740	1,740
Cash & Cash Equivalents	9,285	24,732
Total current assets	89,445	96,230
Total Assets	189,641	196,479
EQUITY		
Share Capital	69,739	69,739
Reserves	87,294	89,708
Treasury Shares	(1,578)	(1,578)
Total Equity	155,455	157,869
LIABILITIES		
Deferred Tax Liability	3,627	3,821
Long Term Borrowings	6,249	10,416
Total non-current liabilities	9,876	14,237
Trade & Other Payables	14,429	13,509
Amount due to related company	697	1,324
Provision	850	850
Taxation	-	356
Term Loan	8,334	8,334
Total current liabilities	24,310	24,373
Total Liabilities	34,186	38,610
Total Equity & Liabilities	189,641	196,479
Net assets per share (RM)	1.11	1.13

(The Condensed Consolidated Balance Sheet should be read in conjunction with the Audited Financial Statements for the year ended 31 December 2010 and the accompanying explanatory notes attached to the interim financial statements.)



CCM DUOPHARMA BIOTECH BERHAD (524271-W)
(Incorporated in Malaysia)
UNAUDITED CONDENSED CONSOLIDATED CASH FLOW STATEMENT
FOR THE PERIOD ENDED 30 JUNE 2011

	30 June 2011	30 June 2010
	RM '000	RM '000
Cash generated from operations:	10,755	19,243
Income taxes paid	(4,496)	(3,504)
Net cash generated from operating activities	6,259	15,739
Net cash used in investing activities	(2,269)	(17,387)
Cash generated from financing activities		
Dividend paid	(15,270)	(14,229)
Drawdown of term loan	-	9,574
Repayment of term loan	(4,167)	(2,083)
Net cash used in financing activities	(19,437)	(6,738)
Net decrease in cash and cash equivalents	(15,447)	(8,386)
Cash and cash equivalents as at 1 January	24,732	26,999
Cash and cash equivalents as at 31 June (I)	9,285	18,613

(I) Cash and cash equivalents comprise:

	<u>RM '000</u>	<u>RM '000</u>
Cash and bank balances	4,052	6,861
Fixed deposits placed with licensed financial institutions	5,233	11,752
	9,285	18,613

(The Condensed Consolidated Cash Flow Statement should be read in conjunction with the Audited Financial Statements for the year ended 31 December 2010 and the accompanying explanatory notes attached to the interim financial statements.)